ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) (clinicaltrials.gov) - Oct 20, 2026 - P2 | N=21 | Terminated | Sponsor: USWM CT, LLC | N=66 ➔ 21 | Active, not recruiting ➔ Terminated; Enrollment was halted following withdrawal of the U.S. IND. Previously enrolled participants completed treatment and follow-up, after which the study was closed.
Enrollment change • Monotherapy • Trial termination • Oncology • Ovarian Cancer • Solid Tumor • BRCA • MAGEA4 • PARP1
|